Seeking Alpha

Derastone  

View Derastone's Comments BY TICKER:
  • Why I Sold Allergan [View article]
    But do you think it was overvalued?
    What about now?
    Jun 25, 2013. 03:59 PM | Likes Like |Link to Comment
  • Allergan: Is It Still Overvalued? [View article]
    Thanks for your comment, next time I will have to specify what kind of earnings we are talking about.

    For the quarter ended March 31, 2013:
    Allergan reported $0.89 diluted earnings per share attributable to stockholders compared to $0.74 diluted earnings per share attributable to stockholders for the first quarter of 2012.

    Diluted earnings per share for the first quarter of 2013 include the full year 2012 impact of the U.S. Research and Development tax credit, which was signed into law on January 2, 2013 and retroactively reinstated to January 1, 2012.

    The estimated impact of the retroactive Research and Development tax credit for 2012 is approximately $17.3 million, or $0.06 diluted earnings per share attributable to stockholders for the first quarter of 2013.

    Allergan reported $0.98 non-GAAP diluted earnings per share attributable to stockholders compared to $0.83 non-GAAP diluted earnings per share attributable to stockholders for the first quarter of 2012, an 18.1 percent increase.

    Non-GAAP diluted earnings per share attributable to stockholders exclude the full year 2012 impact of the U.S. Research and Development tax credit.

    Source: http://bit.ly/16OEenX
    May 6, 2013. 04:50 PM | Likes Like |Link to Comment
  • Allergan, Guilty Pleas and Federal Health Programs [View article]
    Great article!
    Sep 14, 2010. 09:52 AM | Likes Like |Link to Comment
More on AGN by Derastone
COMMENTS STATS
55 Comments
57 Likes